![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1381819
¼¼°èÀÇ ½ÉÀå ÀÓÇöõÆ® ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ±â±â À¯Çüº°, ¿ëµµº°, Áö¿ªº° ºÐ¼®(2023-2030³â)Global Cardiac Implants Market Size study & Forecast, by Device type, Application and Regional Analysis, 2023-2030 |
½ÉÀå ÀÓÇöõÆ® ½ÃÀåÀº ½ÉÇ÷°ü Áúȯ ¹ßº´·üÀÇ Áõ°¡¿Í ³ëÀÎ Àα¸ÀÇ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
¹Ì±¹½ÉÀåÇùȸ(American Heart Association)ÀÇ º¸°í¿¡ µû¸£¸é 2020³â Àü ¼¼°è ÇãÇ÷¼º ½ÉÀ庴(IHD) ȯÀÚ ¼ö´Â 2¾ï 4,410¸¸ ¸íÀ¸·Î ÃßÁ¤µÇ¸ç, ¿©¼ºº¸´Ù ³²¼ºÀÇ À¯º´·üÀÌ ´õ ³ôÀº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ´Â 2020³â ¹Ì±¹ 20¼¼ ÀÌ»ó ¼ºÀÎ Áß ¾à 2,010¸¸ ¸íÀÌ °ü»óµ¿¸ÆÁúȯ(CAD)À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ´Â ¹Ì±¹¿¡¼ °¡Àå ÈçÇÑ ½ÉÀå ÁúȯÀ̶ó°í º¸°íÇß½À´Ï´Ù. ´ç´¢º´, °úüÁß ¹× ºñ¸¸, ºÒ°ÇÀüÇÑ ½Ä½À°ü, ¿îµ¿ ºÎÁ·, °úµµÇÑ À½ÁÖ µîÀÇ ¿äÀÎÀÌ ½ÉÀ庴 ¹ß»ý¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ½ÉÇ÷°ü°è ÁúȯÀÇ ºóµµ°¡ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó, ÀÌ·¯ÇÑ ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µéÀº ½ÉÀå ÀÓÇöõÆ® »ç¿ëÀ» Æ÷ÇÔÇÑ ¿Ü°úÀû ½Ã¼úÀ» ¼±ÅÃÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
½ÉÀå ÀÓÇöõÆ®°¡ ³Î¸® º¸±ÞµÇ°í ÀÖ´Â ÀÌÀ¯´Â ½ÉÇ÷°ü ÁúȯÀ» Ä¡·áÇϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ È¿°úÀûÀ̱⠶§¹®ÀÔ´Ï´Ù. ÀÌ ÀÓÇöõÆ®´Â ºñÁ¤»óÀûÀÎ ½ÉÀå ¸®µë, ½ÉºÎÀü ¹× ±âŸ ½ÉÀå ÁúȯÀ» °ü¸®ÇÏ°í ½ÉÀå¿¡ ÇÊ¿äÇÑ Áö¿ø°ú ±â´ÉÀ» Á¦°øÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±× °á°ú, ½ÉÀå ÀÓÇöõÆ® ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ƯÁ¤ ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡ À¯ÀÇÇØ¾ß ÇÕ´Ï´Ù. ½ÉÀå ÀÓÇöõÆ®ÀÇ ³ôÀº ºñ¿ëÀº ÀϺΠȯÀڵ鿡°Ô Á¢±Ù À庮ÀÌ µÇ¾î µµÀÔÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ÀÓÇöõÆ®¿Í °ü·ÃµÈ ºÎÀÛ¿ë ¹× ÇÕº´Áõ °¡´É¼ºÀ¸·Î ÀÎÇØ ȯÀÚÀÇ °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡°Å³ª ½ÉÀå ÀÓÇöõÆ® ¼ö¼úÀ» ¹Þ´Â °ÍÀ» ÁÖÀúÇÏ´Â »ç¶÷µéµµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸ÇÏ°í ½ÉÇ÷°ü ÁúȯÀÇ Áõ°¡¿Í ½ÉÀå ÀÓÇöõÆ® ¼ö¿ëÀÇ È®´ë´Â ½ÃÀåÀÇ ¼ºÀå ±Ëµµ¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü, Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß ³ë·Â, ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±Àº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÏ°í ½ÉÀå ÀÓÇöõÆ® ¼ö¼úÀÇ È¿´ÉÀ» Çâ»ó½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°è ½ÉÀå ÀÓÇöõÆ® ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ¿©·¯ °¡Áö ¿äÀÎÀ¸·Î ÀÎÇØ ½ÉÀå ÀÓÇöõÆ® ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)´Â ¹Ì±¹¿¡¼ ½ÉÀå ÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö°¡ 2019³â 659,041¸í, 2020³â 69,882¸íÀ¸·Î Áõ°¡Çß´Ù°í º¸°íÇßÀ¸¸ç, CDC´Â °íÇ÷¾Ð, ´ç´¢º´, °íLDL ÄÝ·¹½ºÅ×·Ñ, Èí¿¬À» ½ÉÀ庴°ú ³úÁ¹ÁßÀÇ ÁÖ¿ä À§Çè ¿äÀÎÀ¸·Î ²Å°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ CDC´Â 2030³â±îÁö ¹Ì±¹¿¡¼ ¾à 1,210¸¸ ¸íÀÌ ½É¹æ¼¼µ¿À» ¾ÎÀ» °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÉÇ÷°ü Áúȯ À¯º´·ü Áõ°¡´Â ½ÉÀå ÀÓÇöõÆ® »ç¿ë¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÁÖ¿ä ½ÃÀå ÁøÀÔ ¾÷üµéÀÇ ½ÅÁ¦Ç° Ãâ½Ã¿Í ½ÂÀÎÀº ºÏ¹Ì ½ÉÀå ÀÓÇöõÆ® ½ÃÀå ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Abbott´Â 2022³â 2¿ù ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ CardioMEMS HF ½Ã½ºÅÛÀÇ ÀûÀÀÁõ È®´ë ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ȯÀÚÀÇ Æóµ¿¸Æ¿¡ À̽ÄÇÏ´Â ¼ÒÇü ¼¾¼·Î ±¸¼ºµÇ¾î ½ÉºÎÀü ȯÀÚÀÇ Ä¡·á¸¦ µ½½À´Ï´Ù. ¶ÇÇÑ, 2022³â 4¿ù¿¡´Â ½ÉÀå ¹Úµ¿ÀÌ ´À¸° ȯÀÚ¸¦ Ä¡·áÇÏ´Â ¾Æº£ÀÏ ´ÜÀÏ Ã¨¹ö(VR) ½É¹ÚÁ¶À²±â(VR)ÀÇ FDA ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀü°ú Á¦Ç° Ãâ½Ã´Â »ç¿ë °¡´ÉÇÑ Ä¡·á ¿É¼ÇÀ» °ÈÇϰí ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï »óȲ°ú Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.
The cardiac implants market is being driven by the rise in the incidence of cardiovascular diseases and the growing geriatric population. A report from the American Heart Association revealed that in 2020, there were an estimated 244.1 million cases of ischemic heart disease (IHD) globally, with a higher prevalence in males compared to females. Additionally, the Centers for Disease Control and Prevention reported that in 2020, approximately 20.1 million adults aged 20 and older in the United States had coronary heart disease (CAD), making it the most common type of heart disease in the country. Factors such as diabetes, overweight or obesity, an unhealthy diet, physical inactivity, and excessive alcohol use contribute to the occurrence of heart disease. As the frequency of cardiovascular illnesses continues to rise worldwide, individuals affected by these conditions are increasingly opting for surgical procedures, including the use of cardiac implants, which is driving the market growth.
The growing acceptance of cardiac implants can be attributed to their effectiveness in treating cardiovascular diseases and improving patients' quality of life. These implants help in managing abnormal heart rhythms, heart failure, and other cardiac conditions, providing necessary support and functionality to the heart. As a result, the cardiac implants market is expected to witness significant growth in the coming years. However, it is important to note that certain factors may restrain the market's growth. The high cost of cardiac implants can be a barrier to access for some patients, limiting their adoption. Additionally, there may be potential side effects and complications associated with these implants, which can impact patient outcomes and deter some individuals from pursuing cardiac implant procedures. Despite these challenges, the rise in cardiovascular diseases and the increasing acceptance of cardiac implants indicate a growth trajectory for the market. Continued advancements in technology, ongoing research and development efforts, and improvements in healthcare infrastructure are expected to further drive market growth and enhance the effectiveness of cardiac implant procedures.
The key regions considered for the Global Cardiac Implants Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America holds a significant market share in the cardiac implants market, driven by various factors. The Centers for Disease Control and Prevention (CDC) reports an increase in the number of deaths due to heart diseases in the United States, with 659,041 reported in 2019 and 690,882 in 2020. The CDC identifies high blood pressure, diabetes, high LDL cholesterol, and smoking as key risk factors for heart disease and stroke. Furthermore, the CDC estimates that by 2030, approximately 12.1 million people in the United States will have atrial fibrillation. The growing prevalence of cardiovascular diseases in the region is expected to positively impact the usage of cardiac implants and drive market growth.
The introduction of new products and approvals by key market players further contributes to the growth of the cardiac implants market in North America. For example, Abbott received expanded indication approval from the United States Food and Drug Administration (FDA) for the CardioMEMS HF System in February 2022. This system, consisting of a small sensor implanted in a patient's pulmonary artery, aids in the care of individuals with heart failure. Additionally, in April 2022, Abbott obtained FDA approval for the Aveir single-chamber (VR) leadless pacemaker, which treats patients with slow heart rhythms. These advancements and product launches enhance the treatment options available and drive market growth in the region.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: